Results 161 to 170 of about 3,814,825 (281)

Dapagliflozin does not impair microvascular hemorheology in type 2 diabetes mellitus: A multicenter randomized controlled trial (D‐PATH study)

open access: yesJournal of Diabetes Investigation, EarlyView.
Graphical abstract illustrating the study design, physiological rationale, and key findings of the D‐PATH trial. Dapagliflozin, an SGLT2 inhibitor, lowers HbA1c and body weight while increasing hematocrit and erythropoietin levels. Although an elevated hematocrit could theoretically increase blood viscosity and impair microcirculatory flow, ex vivo ...
Yuki Nakatani   +16 more
wiley   +1 more source

Preparations from selected cucurbit vegetables as antiplatelet agents. [PDF]

open access: yesSci Rep, 2021
Rolnik A, Skalski B, Stochmal A, Olas B.
europepmc   +1 more source

Developing a machine learning model to predict renal function decline within three years using one‐year longitudinal data in patients with type 2 diabetes

open access: yesJournal of Diabetes Investigation, EarlyView.
We developed a machine learning model to predict renal function decline in patients with type 2 diabetes and preserved kidney function. Using one year of routine clinical data, the model forecasts eGFR decline over three years, enabling early identification of high‐risk patients and supporting timely, targeted therapeutic interventions.
Mari Kaneda   +5 more
wiley   +1 more source

Associations of skeletal muscle mass and strength with arterial stiffness in type 2 diabetes

open access: yesJournal of Diabetes Investigation, EarlyView.
Lower skeletal muscle mass and lower handgrip strength were associated with higher arterial stiffness in individuals with type 2 diabetes. Assessment of both parameters may provide complementary information regarding vascular risk. ABSTRACT Sarcopenia is prevalent in people with type 2 diabetes mellitus (T2DM) and may contribute to increased ...
Naoki Koike   +10 more
wiley   +1 more source

Role of comorbidities and medication on immunotherapy efficacy in cSCC: A DeCOG multicentre analysis

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
Immunosuppressive disease was associated with reduced overall survival, while anticoagulant use was linked to prolonged progression‐free survival in advanced cutaneous squamous cell carcinoma treated with immune checkpoint inhibitors. Host‐related factors may modulate immunotherapy efficacy and warrant prospective validation.
Glenn Geidel   +27 more
wiley   +1 more source

How to undertake procedures while on antiplatelet agents: a hematologist's view. [PDF]

open access: yesRes Pract Thromb Haemost
Swan D, Turner R, Douketis J, Thachil J.
europepmc   +1 more source

Home - About - Disclaimer - Privacy